Evaluation of H3K27me3 Expression as a Marker of EZH2 Activation in SMARCA4/SMARCA2-Deficient Tumors and Candidate Biomarker for Trials of EZH2 Inhibitors

被引：0
|
作者：
Kezlarian, Brie [1 ]
Montecalvo, Joseph [2 ]
Sauter, Jennifer [1 ]
Travis, William [1 ]
Gounder, Mrinal [1 ]
Rudin, Charles [1 ]
Ladanyi, Marc [1 ]
Namakydoust, Azadeh [3 ]
Rekhtman, Natasha [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Suny Downstate Med Ctr, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Middletown, NJ USA
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1844
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dynamics of genomic H3K27me3 domains and role of EZH2 during pancreatic endocrine specification
    Xu, Cheng-Ran
    Li, Lin-Chen
    Donahue, Greg
    Ying, Lei
    Zhang, Yu-Wei
    Gadue, Paul
    Zaret, Kenneth S.
    EMBO JOURNAL, 2014, 33 (19): : 2157 - 2170
  • [32] AGE-Induced Suppression of EZH2 Mediates Injury of Podocytes by Reducing H3K27me3
    Liebisch, Marita
    Wolf, Gunter
    AMERICAN JOURNAL OF NEPHROLOGY, 2020, 51 (09) : 676 - 692
  • [33] Prognostic value of immunohistochemical staining for H3K27me3 and EZH2 in astrocytoma, IDH-mutant
    Shumpei Onishi
    Fumiyuki Yamasaki
    Vishwa Jeet Amatya
    Ushio Yonezawa
    Akira Taguchi
    Iori Ozono
    Novita Ikbar Khairunnisa
    Yukari Go
    Yukio Takeshima
    Nobutaka Horie
    Journal of Neuro-Oncology, 2025, 172 (1) : 185 - 194
  • [34] Epigenetic Modifications in Cutaneous Malignant Melanoma: EZH2, H3K4me2, and H3K27me3 Immunohistochemical Expression is Enhanced at the Invasion Front of the Tumor
    Kampilafkos, Panagiotis
    Melachrinou, Maria
    Kefalopoulou, Zinovia
    Lakoumentas, John
    Sotiropoulou-Bonikou, Georgia
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2015, 37 (02) : 138 - 144
  • [35] Strong expression of EZH2 and H3K27me3 is associated with poor survival time in small cell lung cancer
    Fernandes, Ana Paula
    Alves, Rita deCassia S.
    Watte, Guilherme
    Kunze, Philipp
    Roehe, Adriana Vial
    Schneider-Stock, Regine
    CANCER RESEARCH, 2019, 79 (13)
  • [36] High EZH2 Expression Accompanied by Low H3K27me3 Predicts Poorer Outcome in Metaplastic Carcinoma of the Breast
    Tan, Benjamin Yongcheng
    Ong, Clara
    Koh, Valerie
    Thike, Aye Aye
    Tan, Puay-Hoon
    MODERN PATHOLOGY, 2016, 29 : 74A - 75A
  • [37] High EZH2 Expression Accompanied by Low H3K27me3 Predicts Poorer Outcome in Metaplastic Carcinoma of the Breast
    Tan, Benjamin Yongcheng
    Ong, Clara
    Koh, Valerie
    Thike, Aye Aye
    Tan, Puay-Hoon
    LABORATORY INVESTIGATION, 2016, 96 : 74A - 75A
  • [38] Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients
    Liu, Fei
    Gu, Lina
    Cao, Yu
    Fan, Xiaojie
    Zhang, Fengjuan
    Sang, Meixiang
    BIOMARKERS, 2016, 21 (01) : 80 - 90
  • [39] EZH2 inhibitors abrogate upregulation of H3K27me3 by CDK9 inhibitors and potentiate its antitumor activity in DLBCL
    Xie, Shao
    Wei, Fan
    Sun, Yiming
    Gao, Yinglei
    Ding, Jian
    Chen, Yi
    CANCER RESEARCH, 2018, 78 (13)
  • [40] The Methyltransferase EZH2 is not Required for Mammary Cancer Development, Although High EZH2 and Low H3K27me3 Correlate With Poor Prognosis of ER-Positive Breast Cancers
    Bae, Woo Kyun
    Yoo, Kyung Hyun
    Lee, Ji Shin
    Kim, Young
    Chung, Ik-Joo
    Park, Min Ho
    Yoon, Jung Han
    Furth, Priscilla A.
    Hennighausen, Lothar
    MOLECULAR CARCINOGENESIS, 2015, 54 (10) : 1172 - 1180
12345